S2-E7.3 – The newer diabetes drugs and NASH: Educating and Motivating Stakeholders

The panelists consider the barriers to bringing NASH into central consciousness in diabetes therapy and some keys to success.
()

Louise Campbell and Roger Green discuss issues and challenges in educating diabetic patients about NAFLD and NASH. Louise discusses how the rising amount of mortality tied to liver cancer should create a new urgency to broaden focus about the role the liver plays in metabolic health. Roger raises the role that reference labs like Quest and LabCorp have played in driving awareness of underappreciated diseases. The group has several ideas and avenues to explore. Listeners take heed…we have much to figure out and do.

How useful was this post?

Click on a star to rate it!

Average rating / 5. Vote count:

No votes so far! Be the first to rate this post.

Request A Transcript of This Episode
Request Transcript
First
Last

Join The Discussion…

Ask Our Panelists A Question…

Podcast Quesitonaire
Is your question directed towards one of our panelists?

If your question is answered in our next Podcast, would you like be tagged?

Join The Discussion!

Subscribe to our free emails. Receive access to our Discussion Group. Ask your questions directly to our "Surfers"